The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

Table 3 Multivariate Cox regression analysis to identify the outcome predictors

Variables	Hazard ratio [95% CI]	P value
Predictive factors for progression-free survival (PFS)
Afatinib dose (40 mg daily vs. 30 mg daily)	0.40 [0.11–1.49]	0.1722
Sex (male vs. female)	4.45 [1.14–17.42]	0.0322
Smoking history (ever smokers vs. never smokers)	0.19 [0.02–2.24]	0.1867
Number of metastatic sites (≥2 sites vs. ≤1 site)	8.40 [1.90–37.23]	0.0051
Predictive factors for overall survival (OS)
Performance status while starting afatinib (ECOG ≥2 vs. ECOG ≤1)	6.01 [1.30–28.21]	0.0219

*The candidate variables included for selection were afatinib dose, age, sex, smoking history, EGFR mutation site of the cancer specimen, number of metastatic sites, weight, height, estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula, and serum albumin level. Multivariable Cox regression models were built using the backward variable selection method, keeping only variables with p values less than 0.2, to determine the predictive factors for PFS and OS

ISSN: 2050-6511